 | Up a level |
Journal Article
Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Fruehwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I, Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F. H., Theissen, J., Volland, R., Hero, B. and Simon, T. (2020). Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann. Oncol., 31 (3). S. 422 - 430. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Van Zogchel, L., De Carolis, B., van Wezel, E., Stutterheim, J., Zappeij-Kannegieter, L., van Doornum, M., Schumacher-Kuckelkorn, R., Gecht, J., Simon, T., Caron, H., Fiocco, M., van der Schoot, E., Hero, B., Berthold, F. and Tytgat, G. (2018). Detection of Minimal Residual Disease (MRD) in High Risk Neuroblastoma Correlates with Outcome: Final Results of International GPOH-DCOG Prospective Validation Study. Pediatr. Blood Cancer, 65. S. S38 - 1. HOBOKEN: WILEY. ISSN 1545-5017
van Wezel, E., Decarolis, B., Stutterheim, J., Zappeij-Kannegieter, L., Hero, B., Berthold, F., Simon, T., Schumacher-Kuckelkorn, R., van Noesel, M., Fiocco, M., Caron, H., van der Schoot, C. E. and Tytgat, G. (2015). MINIMAL BONE MARROW DISEASE IS FREQUENTLY DETECTED IN LOCALIZED NEUROBLASTOMA PATIENTS. Pediatr. Blood Cancer, 62. S. S226 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017